Healthcare Industry News: Alaris
News Release - June 5, 2007
Cadence Pharmaceuticals Names Hazel Aker, J.D. Senior Vice President, General Counsel and Catherine Hardalo, M.D. Vice President, Clinical DevelopmentSAN DIEGO, June 5 (HSMN NewsFeed) -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Hazel M. Aker, J.D. joins the Cadence executive management team as Senior Vice President, General Counsel and Corporate Secretary. Cadence also welcomes Catherine J. Hardalo, M.D. as Vice President, Clinical Development, to direct the company's anti-infective drug program.
Dr. Hardalo joins Cadence from Schering-Plough Research Institute, a global health care company, where she directed the clinical development of antimicrobial products since 1998. Most recently, she was Senior Director of Infectious Disease and Dermatology Global Clinical Development, and was named one of 20 "notable people in R&D" by R&D Directions in 2007. Dr. Hardalo's past experience also includes solo practice with board certification in infectious diseases and internal medicine. She received her medical degree from the State University of New York Health Science Center at Brooklyn- Downstate Medical College, served as Chief Resident for the Department of Internal Medicine at Morristown Memorial Hospital in New Jersey and was a clinical fellow in Infectious Diseases, Clinical Microbiology and Hospital Epidemiology, at Yale-New Haven Hospital at Yale University School of Medicine. "The knowledge that Dr. Hardalo gained as an infectious disease doctor in the hospital setting and her development experience with big pharma make her an ideal fit to lead our Omigard program," stated Jim Breitmeyer, M.D., Cadence's Executive Vice President and Chief Medical Officer.
About Cadence Pharmaceuticals
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III products in development, including IV APAP, (acetaminophen for injection) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter- related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence's business including, without limitation, the progress and timing of the company's ongoing and planned clinical trials, difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products and other risks detailed in Cadence's prior press releases as well as in Cadence's public filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Source: Cadence Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.